FDA will soon unveil a drug competition plan aimed at getting lower-cost pharmaceuticals to market, agency Commissioner Scott Gottlieb told House appropriators Thursday (May 25), while holding up increased generic competition as a key FDA priority. Gottlieb also said FDA plans to: issue a list of off-patent drugs that lack competition; hold a meeting on ways to prevent abuse of Risk Evaluation and Mitigation Strategies, such as waiving shared REMS requirements more often; issue guidance cutting back the number of...